+139.7%
CIFR vs MRNA
+511.3%
-371.6%
-51.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.1% | -2.2% | +4.4% | +2.2% |
| 7D | +16.9% | +5.5% | +11.5% | +16.8% |
| 30D | -5.2% | +158.7% | -163.9% | -12.2% |
| 3M | -30.6% | +182.1% | -212.7% | -38.3% |
| 6M | +10.6% | +151.8% | -141.2% | +0.3% |
| YTD | +20.2% | +393.6% | -373.4% | -3.0% |
| 1Y | +139.7% | +499.5% | -359.7% | +95.2% |
| All | +139.7% | +511.3% | -371.6% | +95.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling